Excellent talk on EVERYTHING #cdiff by @DrPaulGastro - including #microbiome role in pathogenesis and treatment. Check out his website https://t.co/dS172wwqEg #cdiff2019 @cdiffFoundation

#CdiffWalk2019 "None of us can do this alone 💚 All of us can do this together. " https://t.co/2WcVtLGmMN #microbiome #gutmicrobiota #Cdifficile #CdiffInfo #infectionprevention #Infectioncontrol #CdiffSurvivors #CdiffFree #EverythingCdifficile

Did you miss #DDW19? There was a lot of great research! Check out my video reviews of some of the most impactful abstracts in the #Cdiff space. Providers: https://t.co/7zReT3biiQ Patients: https://t.co/uVnkZWiPK2 More video reviews to come in the coming weeks of other studies

Very excited to attend #DDW19 in San Diego! Looking forward to catching up with colleagues and hearing the latest research! I will be live tweeting about anything #GI Also, through https://t.co/nxTY7ZGWf1, I will post updates with short videos summarizing impactful studies!

#Cdiff guidelines change clinical practice! Check out my video review of a great abstract from @ClancyNeil Patients: https://t.co/waIskr6zdA Providers: https://t.co/fBWU8ZcKqF #idweek2019

@DrJessicaA and colleagues presented excellent work considering #FMT in patients with recurrent #Cdiff and #IBD FMT clears Cdiff and seems to improve IBD symptoms as well Video review: Providers: https://t.co/dsjX39UjNP Patients: https://t.co/gKidGrYItN #DDW19

Should we give vancomycin prophylaxis for our patients at greatest risk for #cdiff? Yes, it works! Check out my video review from an abstract from Dr. Van Hise from #idweek2019 Patient: https://t.co/UafQPhzljo Provider: https://t.co/P710hqcdFx

Based on 2018 #IDSA guidelines what is most effective and cost efficient #cdiff treatment? Initial Non-sev: Fidaxomicin Initial sev: Vancomycin 1st Recur: Fidaxomicin 2nd Recur: #FMT Video review: Providers: https://t.co/bD2yvGxdS5 Patients: https://t.co/bD2yvGxdS5 #DDW19

@Khanna_S and @Tariqraseen presented meta-analyses considering vanco prophylaxis against #Cdiff Vanco prevents recurrence in those at high risk with a trend to decrease initial infection Video review: Providers: https://t.co/zyLr9bVy1m Patients: https://t.co/ycSBlnY6BA #DDW19

Pts w increasing #Cdiff recurrences show trends for increased medical co-morbidities, frequency of sepsis and surgical requirement Stong et al. Please check out my video review of this abstract from #ACG2019: Provider: https://t.co/GXRu9SYC0A Patient: https://t.co/geHjhYYAJ3

New def for healthcare associated #Cdiff needed? See my video review of abstract from #IDWeek2019 considering risk of Cdiff 3-6 and 6-12 months after hospitalization Pts in both time frames are at increased risk! Patient: https://t.co/u5pJWouWUH Provider: https://t.co/POfr9rruiT

What are #Symptoms of a #cdiff #infection ? For more information visit https://t.co/wGMiPgPqEv For patients and #healthcare providers #MedEd

#FMT for recurrent #cdiff in a population > 75? Seems safe and similarly effective in those older than 75 at 8-weeks and 1 year after therapy Abdullah et al. Check out my video review of this #ACG2019 Abstract: Provider: https://t.co/eqeNtMaGca Patient: https://t.co/9FYyFZGNla

A #vaccine for #cdiff? It's a possibility Exciting data e-published last week @IDSAInfo showed antibody formation to toxin A/B for a potential vaccine Summary videos: Provider: https://t.co/eDFhJOl3tS Patient: https://t.co/RisRs52xgh https://t.co/vMWPwHiGa3 #meded #IDtwitter

Given recent concerns with safety of #FMT, let's consider the previous reports. In #Cdiff, in most pts, benefits far outweigh risks! @Khanna_S abstract from #DDW19 further supports the long-term safety Review: Provider: https://t.co/Aa97iA8SdW Patient: https://t.co/Hp9frPlILO

Does #FMT improve outcomes in patients with severe or fulminant #cdiff? @Grinsa01 and @RyanUngaro showed this to be a very effective treatment reducing inpatient mortality 73%. Video review: Providers: https://t.co/wgLYSPn8gl Patients: https://t.co/iBFRTiKopM #DDW19

#EverythingCdifficile #cdiff #CDIFFinfo #Cdifficile #guthealth https://t.co/GoPIg1FGcF

~25% of all patients with #cdiff receiving initial treatment are estimated to recur Curious about risk factors for recurrence? Check out my patient or provider based Vlogs: Provider: https://t.co/RN9sj37rAe Patient: https://t.co/D16aedqQ2T #meded #medtwitter

Diagnosis of #Cdiff is complicated A few tips: Know how your hospital tests the stool Try not send repeat stool test after initial diagnosis. Use clinical judgement and treat if you think it has recurred Brief video discussing diagnosis: https://t.co/85Vls5n0L2 #somedocs #meded

Want to know everything about #cdiff ? Check out my friend @DrPaulGastro ‘s website